What is Enliven Therapeutics Scaled Net Operating Assets?
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Enliven Therapeutics's operating assets for the quarter that ended in Mar. 2024 was $22.27 Mil. Enliven Therapeutics's operating liabilities for the quarter that ended in Mar. 2024 was $24.81 Mil. Enliven Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $271.87 Mil. Therefore, Enliven Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was -0.01.
Enliven Therapeutics Scaled Net Operating Assets Historical Data
The historical data trend for Enliven Therapeutics's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enliven Therapeutics Scaled Net Operating Assets Chart
|
Enliven Therapeutics Annual Data
|
|
Trend |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Scaled Net Operating Assets |
|
-1.15 |
-1.17 |
-1.34 |
-0.08 |
|
Enliven Therapeutics Quarterly Data
|
|
Dec20 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
Mar24 |
| Scaled Net Operating Assets |
Get a 7-Day Free Trial
|
|
|
|
|
- |
0.01 |
-0.01 |
-0.03 |
-0.01 |
Competitive Comparison of Enliven Therapeutics's Scaled Net Operating Assets
For the Biotechnology subindustry, Enliven Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enliven Therapeutics's Scaled Net Operating Assets Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enliven Therapeutics's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Enliven Therapeutics's Scaled Net Operating Assets falls into.
Enliven Therapeutics Scaled Net Operating Assets Calculation
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Enliven Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as
| Scaled Net Operating Assets (SNOA) | | (A: Dec. 2023 ) |
| = | (Operating Assets (A: Dec. 2023 ) | - | Operating Liabilities (A: Dec. 2023 )) | / | Total Assets (A: Dec. 2022 ) |
| = | (18.719 | - | 25.626) | / | 83.298 |
| = | -0.08 |
where
Enliven Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as
| Scaled Net Operating Assets (SNOA) | | (Q: Mar. 2024 ) |
| = | (Operating Assets (Q: Mar. 2024 ) | - | Operating Liabilities (Q: Mar. 2024 )) | / | Total Assets (Q: Dec. 2023 ) |
| = | (22.273 | - | 24.813) | / | 271.867 |
| = | -0.01 |
where
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enliven Therapeutics (Enliven Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
6200 Lookout Road, Boulder, CO, USA, 80301
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially best-in-class or first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases.
Executives
| Anish Patel |
officer: Chief Operating Officer |
C/O ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301 |
| Benjamin Hohl |
officer: Chief Financial Officer |
6200 LOOKOUT ROAD, BOULDER CO 80301 |
| Joseph P Lyssikatos |
director, officer: Chief Scientific Officer |
6200 LOOKOUT ROAD, BOULDER CO 80301 |
| Samuel Kintz |
director, officer: President and CEO |
ENLIVEN THERAPEUTICS INC, 6200 LOOKOUT ROAD, BOULDER CO 80301 |
| Richard A. Heyman |
director |
5871 OBERLIN DRIVE, SUITE 150, SAN DIEGO CA 92121 |
| 5am Partners Vi, Llc |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Rishi Gupta |
director, 10 percent owner |
C/O CHEMOCENTRYX, INC., 850 MAUDE AVENUE, MOUNTAIN VIEW CA 94043 |
| Andrew J. Schwab |
director |
C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Helen Louise Collins |
director |
TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
| Jake Bauer |
director |
C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080 |
| 5am Opportunities I, L.p. |
10 percent owner |
501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| 5am Opportunities I (gp), Llc |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| Orbimed Genesis Gp Llc |
10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
| Kush Parmar |
10 percent owner |
C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
| 5am Ventures Vi, L.p. |
10 percent owner |
501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107 |
Enliven Therapeutics (Enliven Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ELVN has been successfully added to your